April Wurster helps clients navigate complex issues related to law and technology. Her day-to-day practice focuses on intellectual property and life sciences transactions.
April uses cross-functional knowledge and experience to build a thorough understanding of a company's business, employees, products, customers, and competitors to provide strategic guidance. She works in new subject matter areas on a daily basis, assimilating information quickly and developing a deep understanding in those areas. April excels at distilling complex ideas into understandable concepts.
Patent: April assists clients from early- and mid-stage startups to public companies with protecting their intellectual property across a diverse range of industries, including cell and gene therapies, therapeutics, SaaS, pharmaceuticals, diagnostic tests, and medical devices. April has extensive experience conducting Freedom to Operate analyses, collaborating with scientific and technical personnel to identify patentable inventions, and drafting and prosecuting patents.
Trademark: April advises international and U.S. companies on trademark matters, including trademark clearances, ensuring proper trademark usage on product marketing materials, trademark enforcement, licenses, filing and prosecuting trademark applications. April routinely counsels clients regarding name changes and brand name selection.
April advises clients on trade secret protections, such as identifying key trade secrets, creating trade secret registries, and developing policies for protecting trade secrets, which may include amending contracts, marking documents as trade secrets, putting access restriction controls on documents containing trade secrets, and training employees.
Life Sciences Transactions
April is a member of the firm’s Life Science and Medical Technology Industry Group. She provides commercial contracting advice to regenerative medicine, CDMOs, CROs, medical device, and diagnostics clients. April is well-versed in the legal requirements of regenerative medicine and CDMO clients, including their regulatory framework requirements, rapidly evolving technology, and competitive landscape. She has vast experience negotiating pre-clinical and clinical trial agreements, material transfer agreements, master service agreements, master research and development agreements, joint development agreements, collaborative research agreements, licenses, strategic alliances, acquisitions, manufacturing and supply agreements, quality agreements (R&D, manufacturing, and clinical trial), data privacy agreements, clinical study agreements, and SaaS agreements.
April serves as a trusted advisor for matters related to trademarks, copyright, and patents, drawing upon her broad experience with each aspect of the litigation lifecycle, from filing and discovery to jury trial or settlements.
Former general counsel to a San Francisco based oncology diagnostic company overseeing the legal team and serving as a key advisor to the board
Oversaw a San Diego based diagnostic company’s intellectual property strategy and enforcement, including protection of new ideas, management of the company’s patent and trademark portfolio, and working with business units to ensure intellectual property is identified and protected including IP assessments for the release of four COVID-19 detection assays in 2020
Managed a San Diego based medical device company’s IP portfolio by working directly with engineers and scientists to identify patentable inventions, filing patent applications, conducting freedom-to-operate searches, analyzing office actions from the USPTO and foreign patent offices and preparing responses
University of California, Hastings College of Law (J.D., 2003)
Intellectual Property Organization
University of California, San Diego (M.S., Molecular Biology, 2000)
University of California, San Diego (B.S., Biochemistry and Cell Biology, 1999)
“Willful Infringement Is A State of Mind,” Co-Author, Global Intellectual Property Asset Management Report (August 2006)
“Genetic Discrimination: Health Insurance For The Genetically Lucky And The Genetically Unlucky,” Co-Author, Medical Trial Techniques Quarterly (July 2004)
“Genetic Discrimination In Insurance Law: An Ethical Perspective,” Co-Author, Medical Trial Techniques Quarterly, Vol. 50, No. 4, 95-119 (2004)
"Current Issues In Biotech: 271(e)(l)," Presenter, Western School of Law (March 5, 2005)
“Will The Federal Circuit Eliminate The Opinion Letter Requirement?” Co-Author, The Daily Transcript (May 4, 2004)
"Adverse Inferences in Willful Patent Infringement Cases – The Knorr-Bremse Issue," Presenter, Orange County Patent Law Association (March 27, 2004)
"PGD – Does it 'Promote the Progress of Science and Useful Arts?'" Presenter, Stanford Law School (February 27, 2004)
“Epidermal Stem Cell Frequency: A Novel In Vivo Functional Assay,” Co-Author, The American Society of Cell Biology (2003)
“Measuring Stem Cell Frequency I Epidermis: A Quantitative In Vivo Functional Assay For Long-Term Repopulating Cells,” Co-Author, Proceedings of the National Academy of Science 100(20):11412-7 (September 30, 2003)
“Stem Cell Frequency In Murine Epidermis: A Novel In Vivo Functional Assay For Epidermal Stem Cells,” Co-Author, Proceedings of the National Academy of Science (September 2003)
“A Novel Functional In Vivo Epidermal Stem Cell Assay,” Co-Author, Journal of Investigative Dermatology (August 2002)
“Stem Cell Frequency In Murine Epidermis Is 1 in 26,000: A Novel In Vivo Functional Assay For Epidermal Stem Cells,” Co-Author, American Journal of Cell Biology (2002)